Mega Genomics 06667 Prospectus Information

Company Overview

Stock Name	Mega Genomics
Stock Code	06667
Company Full Name	To be extracted
Industry	醫療保健
Principal Activities	主要在中國提供消費級基因檢測及癌癥篩查服務。
Listing Date	2022-06-22
Listing Rules Era	Old Rules
Listing Rules Chapter	To be extracted
Weighted Voting Rights (WVR)	No
Registered Address (Mainland China)	中國北京市海淀區花園北路健康智谷401
Business Address (Hong Kong)	To be extracted
Place of Incorporation	To be extracted
Listing Method	To be extracted
Listing Board	Main Board
Website	https://www.megagenomics.cn
Share Registrar	卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact	(852)2980 1333
A-Share/US Dual Listing	No data

Offering Information

Offering Mechanism	To be extracted
Offer Price	HK$ 18.00 / shares
Offer Price Range	To be extracted
Lot Size	To be extracted
Entry Threshold	To be extracted
Par Value	To be extracted
Offer Period	To be extracted
Global Offering Shares	To be extracted
HK Public Offer Shares (Initial)	To be extracted
Public Offer Lots (Initial)	To be extracted
International Placing Shares (Initial)	To be extracted
Offer Ratio	To be extracted
Total Shares Post-IPO	To be extracted
Greenshoe (Over-allotment Option)	To be confirmed
Stabilizing Manager (Greenshoe)	—
Cornerstone Share	81.0%
Clawback Tiers	To be extracted
Reallocation Option	To be confirmed
Total Global Offering Size	HK$ 21,531,600

Stock Connect Inclusion

HK Market Cap	---

26Q2 Regular Review
Inclusion Pathway	None
Est. Threshold	---
Analysis Result	无法确定入通路径

Valuation & Financials

Market Cap (at Offer Price)	To be extracted
Pre-IPO Valuation (Last Round)	Not disclosed
P/E Ratio	Not disclosed
Profit/Loss Status	To be extracted
Period-End Cash Balance	To be extracted
Listing Expenses	To be extracted
Listing Expenses / Funds Raised	To be extracted
Total Pre-IPO Investment	To be extracted

First Day Performance

First Day Close	HK$ 18.0
First Day Open	HK$ 19.48
First Day Change	-61.39%
First Day Volume	3858800.0
First Day Turnover	74244600.0

Use of Proceeds

Use of Proceeds	1、約30%或46.0百萬港元將用于我們的消費級基因檢測及癌癥篩查服務及產品的銷售、營銷及商業化； 2、約25%或38.4百萬港元將投資于研發我們的服務及產品； 3、約20%或30.7百萬港元將用于增加或擴大我們的檢測能力及產能； 4、約15%或23.0百萬港元將用于通過投資或收購具吸引力的技術或檢測相關公司，為我們在整個行業價值鏈的擴張提供資金； 5、約10%或15.3百萬港元預期將用作營運資金及其他一般企業用途。

1、約30%或46.0百萬港元將用于我們的消費級基因檢測及癌癥篩查服務及產品的銷售、營銷及商業化； 2、約25%或38.4百萬港元將投資于研發我們的服務及產品； 3、約20%或30.7百萬港元將用于增加或擴大我們的檢測能力及產能； 4、約15%或23.0百萬港元將用于通過投資或收購具吸引力的技術或檢測相關公司，為我們在整個行業價值鏈的擴張提供資金； 5、約10%或15.3百萬港元預期將用作營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)

China Securities (International) Corporate Finance Company Limited CE BAU112

Overall Coordinators (3)

China Securities (International) Corporate Finance Company Limited CE BAU112 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855

Joint Bookrunners (7)

China Securities (International) Corporate Finance Company Limited CE BAU112 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 Futu Securities International (Hong Kong) Limited CE AZT137 Tiger Brokers (HK) Global Limited CE BMU940 Livermore Holdings Limited CE BJN764 GUOTAI JUNAN SECURITIES (HONG KONG) LIMITED CE ABY236

Joint Lead Managers (7)

Cornerstone Investors

#	Investor Name	Investment Amount	Shares Subscribed	% of Offer Shares	% of Total Shares	Lock-up Period	Est. Unlock Date
1	迈克生物股份有限公司	58,158,000 HKD	—	27.01%	—	6 months	2022-12-22
2	南昌工控园区股权投资合伙企业(有限合伙)	81,414,000 HKD	—	37.81%	—	6 months	2022-12-22
3	南昌金融控股有限公司	34,898,400 HKD	—	16.21%	—	6 months	2022-12-22

Directors & Management

Chairman	林琳
Company Secretary	吳嘉智

No director data available.

Major Shareholders

Major Shareholders & Holdings	美年大健康產業控股股份有限公司(15.57%);俞熔(9.53%);郭美玲(9.2%);天津世紀宇能企業管理合伙企業(有限合伙)(5.06%)

Mega Genomics 06667Prospectus Information